DYSCOVRY SCIENCE LTD is an innovative Toronto-based biotechnology company conducting research to establish a world-leading position in the development of fungal- and plant-derived therapeutics through its proven drug discovery and development processes, its growing intellectual property portfolio, and regulatory and manufacturing expertise.
Dyscovry is led by an experienced team with government, university and private partnerships focussing on biosynthesis of psilocybin and investigating a quantifiable anti-inflammatory effect of psychedelics – believed to be mediated through 5-HT2A activation – and how this relationship pertains to disorders that affect the large intestine. We are are focused on indications such as Irritable Bowel Syndrome (IBS) that inflict suffering on a double digit percentage of the entire human global population. This suffering includes the physiological symptoms but also the secondary psychological symptoms from living with this disease.
Dyscovry has embarked on the rigorous scientific investigation of enhanced biosynthesis of psilocybin as an alternative therapeutic option to both naturally occurring and chemically synthesized psilocybin. This will not only allow for the future wide-scale production, but also fuel Dyscovry’s mission to unlock the potential for psilocybin in addressing a variety of disorders with the goal of developing safe, FDA and Health Canada approved therapies
Dyscovry’s downstream goal is to bring regenerative medicine approaches to the treatment of IBS. We propose to develop translational approaches that will enable the utilization of human embryonic stem cells for therapeutic applications in gastrointestinal bowel diseases, including IBS and inflammatory bowel disease. If the aims of the research are achieved, our findings will make a critical contribution to development of urgently needed therapeutics.
Sign up to receive updates, news, and more.
Dyscovry Science Ltd.
Copyright © 2022 Dyscovry Science Ltd. - All Rights Reserved.